Studies have shown that dysregulated Eph/ephrin signaling pathway could lead to synaptic deficits associated with AD and suggest that Eph/ephrin signaling pathway could act as a target for new therapeutic opportunities for AD (94, 95). The gene discussed is EPHA1; the disease is Alzheimer disease.